Curis to Present at Upcoming Healthcare Conference in July
Curis to Present at Upcoming Healthcare Conference in July
LEXINGTON, Mass., July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m. PT (11:00 a.m. ET). A live webcast and archived replay will be available and can be accessed here or on the Events & Presentations section of Curis's website.
2024年7月10日,马萨诸塞州列克星敦 / PRNewswire - 生物技术公司Curis,Inc.(NASDAQ:CRIS)专注于开发口服小分子IRAK4抑制剂emavusertib(CA-4948),今天宣布,Curis的总裁兼首席执行官James Dentzer将于2024年7月15日上午8:00(太平洋时间),下午11:00(东部时间)在Jones Healthcare Seaside Summit 2024上发表演讲。可在线收听直播和归档重播,点击此处或访问Curis网站的活动与演示部分。
About Curis, Inc.
关于Curis,Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge to Genentech, a member of the Roche Group, under which they are commercializing Erivedge for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at
Curis是一家生物技术公司,致力于开发口服小分子IRAK4抑制剂emavusertib。emavusertib目前正在进行第1/2期TakeAim淋巴瘤研究,研究对象是患有复发性/难治性原发性中枢神经系统淋巴瘤(PCNSL)的患者,在与BTk抑制剂ibrutinib联合使用的情况下,作为单药用于复发性/难治性急性髓细胞白血病(AML)和携带FLT3突变或剪接因子突变(U2AF1或SF3B2)的高危骨髓增生异常综合征(hrMDS)患者的第1/2期TakeAim白血病研究,以及与azacitidine和venetoclax合并用于AML患者的一线组合疗法。emavusertib已获得美国食品和药物管理局授予的治疗AML和MDS的孤儿药物认证。Curis通过与Aurigene的2015年合作拥有emavusertib (CA-4948) 的独家许可。Curis已将其对Erivedge的权利许可给了Roche旗下的Genentech,用于开发用于治疗晚期基底细胞癌的Erivedge。更多信息,请访问Curis网站的网站。
SOURCE Curis, Inc.
来源:Curis股份有限公司。